Inhibitory effects of Morinda citrifolia extract and its constituents on melanogenesis in murine B16 melanoma cells. 2012

Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
Faculty of Pharmacy, Kinki University, 3–4–1 Kowakae, Higashiosaka, Osaka 577–8502, Japan.

The objective of this study was to examine the effects of Morinda citrifolia (noni) extract and its constituents on α-melanocyte stimulating hormone (α-MSH)-stimulated melanogenesis in cultured murine B16 melanoma cells (B16 cells). A 50% ethanolic extract of noni seeds (MCS-ext) showed significant inhibition of melanogenesis with no effect on cell proliferation. MCS-ext was more active than noni leaf and fruit flesh extracts. Activity guided fractionation of MCS-ext led to the isolation of two lignans, 3,3'-bisdemethylpinoresinol (1) and americanin A (2), as active constituents. To elucidate the mechanism of melanogenesis inhibition by the lignans, α-MSH-stimulated B16 cells were treated with 1 (5 μM) and 2 (200 μM). Time-dependent increases of intracellular melanin content and tyrosinase activity, during 24 to 72 h, were inhibited significantly by treatment with the lignans. The activity of 1 was greater than that of 2. Western blot analysis suggested that the lignans inhibited melanogenesis by down regulation of the levels of phosphorylation of p38 mitogen-activated protein kinase, resulting in suppression of tyrosinase expression.

UI MeSH Term Description Entries
D008543 Melanins Insoluble polymers of TYROSINE derivatives found in and causing darkness in skin (SKIN PIGMENTATION), hair, and feathers providing protection against SUNBURN induced by SUNLIGHT. CAROTENES contribute yellow and red coloration. Allomelanins,Melanin,Phaeomelanins
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D004147 Dioxins A family of compounds that contain the 1,4-dioxin structure. Many specific dioxin derivatives are listed as CARCINOGENS; TERATOGENS; or MUTAGENS. Dioxin
D000521 alpha-MSH A 13-amino acid peptide derived from proteolytic cleavage of ADRENOCORTICOTROPIC HORMONE, the N-terminal segment of ACTH. ACTH (1-13) is amidated at the C-terminal to form ACTH (1-13)NH2 which in turn is acetylated to form alpha-MSH in the secretory granules. Alpha-MSH stimulates the synthesis and distribution of MELANIN in MELANOCYTES in mammals and MELANOPHORES in lower vertebrates. MSH, alpha,alpha Intermedin,alpha-Melanocyte-Stimulating Hormone,(Des-Acetyl)-alpha-MSH,(Desacetyl)alpha-MSH,ACTH (1-13),ACTH (1-13)NH2,ACTH(1-13),Acetylated ACTH (1-13)NH2,Adrenocorticotropin (1-13)NH2,DE-alpha-MSH,Des-Acetyl MSH,Desacetyl alpha-MSH,Desacetyl alpha-Melanocyte-Stimulating Hormone,MSH, (Desacetyl)alpha-,alpha-Melanotropin,Desacetyl alpha MSH,Desacetyl alpha Melanocyte Stimulating Hormone,Hormone, Desacetyl alpha-Melanocyte-Stimulating,Hormone, alpha-Melanocyte-Stimulating,Intermedin, alpha,MSH, Des-Acetyl,alpha MSH,alpha Melanocyte Stimulating Hormone,alpha Melanotropin,alpha-MSH, Desacetyl,alpha-Melanocyte-Stimulating Hormone, Desacetyl
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014442 Monophenol Monooxygenase An enzyme of the oxidoreductase class that catalyzes the reaction between L-tyrosine, L-dopa, and oxygen to yield L-dopa, dopaquinone, and water. It is a copper protein that acts also on catechols, catalyzing some of the same reactions as CATECHOL OXIDASE. EC 1.14.18.1. Dopa Oxidase,Phenoloxidase,Tyrosinase,Cresolase,Phenol Oxidase,Phenoloxidase A,Phenoloxidase B,Monooxygenase, Monophenol,Oxidase, Dopa,Oxidase, Phenol
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D017705 Lignans A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Lignan,Neolignan,Neolignans

Related Publications

Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
September 2010, Phytotherapy research : PTR,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
October 2004, Biological & pharmaceutical bulletin,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
July 2009, Journal of natural medicines,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
July 2014, Pharmacognosy research,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
January 2012, Bioscience, biotechnology, and biochemistry,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
April 2008, Bioscience, biotechnology, and biochemistry,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
January 2011, Bioscience, biotechnology, and biochemistry,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
October 2009, Journal of natural medicines,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
June 2012, Chemistry & biodiversity,
Megumi Masuda, and Kimihisa Itoh, and Kazuya Murata, and Shunsuke Naruto, and Akemi Uwaya, and Fumiyuki Isami, and Hideaki Matsuda
April 2014, Natural product communications,
Copied contents to your clipboard!